Correlation Between DiaMedica Therapeutics and Milestone Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both DiaMedica Therapeutics and Milestone Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining DiaMedica Therapeutics and Milestone Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between DiaMedica Therapeutics and Milestone Pharmaceuticals, you can compare the effects of market volatilities on DiaMedica Therapeutics and Milestone Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in DiaMedica Therapeutics with a short position of Milestone Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of DiaMedica Therapeutics and Milestone Pharmaceuticals.

Diversification Opportunities for DiaMedica Therapeutics and Milestone Pharmaceuticals

0.36
  Correlation Coefficient

Weak diversification

The 3 months correlation between DiaMedica and Milestone is 0.36. Overlapping area represents the amount of risk that can be diversified away by holding DiaMedica Therapeutics and Milestone Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Milestone Pharmaceuticals and DiaMedica Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on DiaMedica Therapeutics are associated (or correlated) with Milestone Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Milestone Pharmaceuticals has no effect on the direction of DiaMedica Therapeutics i.e., DiaMedica Therapeutics and Milestone Pharmaceuticals go up and down completely randomly.

Pair Corralation between DiaMedica Therapeutics and Milestone Pharmaceuticals

Given the investment horizon of 90 days DiaMedica Therapeutics is expected to generate 1.14 times more return on investment than Milestone Pharmaceuticals. However, DiaMedica Therapeutics is 1.14 times more volatile than Milestone Pharmaceuticals. It trades about 0.19 of its potential returns per unit of risk. Milestone Pharmaceuticals is currently generating about 0.2 per unit of risk. If you would invest  389.00  in DiaMedica Therapeutics on September 2, 2024 and sell it today you would earn a total of  177.00  from holding DiaMedica Therapeutics or generate 45.5% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

DiaMedica Therapeutics  vs.  Milestone Pharmaceuticals

 Performance 
       Timeline  
DiaMedica Therapeutics 

Risk-Adjusted Performance

14 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in DiaMedica Therapeutics are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, DiaMedica Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point.
Milestone Pharmaceuticals 

Risk-Adjusted Performance

15 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Milestone Pharmaceuticals are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady basic indicators, Milestone Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point.

DiaMedica Therapeutics and Milestone Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with DiaMedica Therapeutics and Milestone Pharmaceuticals

The main advantage of trading using opposite DiaMedica Therapeutics and Milestone Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if DiaMedica Therapeutics position performs unexpectedly, Milestone Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Milestone Pharmaceuticals will offset losses from the drop in Milestone Pharmaceuticals' long position.
The idea behind DiaMedica Therapeutics and Milestone Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Other Complementary Tools

Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital